文献速递乳腺癌

SB3曲妥珠单抗生物类似药与参照药新辅助治疗HER2阳性早期乳腺癌的III期随机双盲研究

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.
PubMed 文献 · J Clin Oncol · 2018-01-26

这项III期随机双盲研究比较了SB3曲妥珠单抗生物类似药与参照曲妥珠单抗在HER2阳性早期乳腺癌新辅助治疗中的疗效、安全性和免疫原性。主要终点为乳腺病理完全缓解率(bpCR),SB3组为51.7%,参照药组为42.0%,调整后比值1.259(95%CI 1.085-1.460)在预设等效界值内,证实疗效等效,安全性和免疫原性相当。

要点

  • SB3与参照曲妥珠单抗的bpCR率分别为51.7%和42.0%,调整后比值1.259(95%CI 1.085-1.460),落在等效界值内。
  • 安全性方面,两组不良事件发生率分别为96.6%和95.2%,严重不良事件为10.5%和10.7%,抗药抗体为0.7%和0.0%。
  • SB3组总病理完全缓解率和总缓解率数值上略高,但研究主要目的是等效性而非优效性。

核心结论

  • 基于bpCR率的比值,SB3与参照曲妥珠单抗在疗效上等效,安全性和免疫原性相当。

研究设计与样本

  • III期随机双盲研究,纳入HER2阳性早期乳腺癌患者,随机接受新辅助SB3或参照曲妥珠单抗8周期联合化疗,术后继续辅助治疗10周期。

主要发现

  • SB3组和参照药组的bpCR率分别为51.7%和42.0%,调整后比值1.259(95%CI 1.085-1.460),在预设等效界值0.785-1.546内。
  • 调整后差值10.70%(95%CI 4.13%-17.26%),下限在等效界值内但上限超出。
  • 总病理完全缓解率分别为45.8%和35.8%,总缓解率分别为96.3%和91.2%。
  • 不良事件发生率分别为96.6%和95.2%,严重不良事件分别为10.5%和10.7%,抗药抗体(至第9周期)分别为0.7%和0.0%。

关键数值与推荐

  • 主要终点为符合方案集中的bpCR率,等效性定义为比值的95%CI在0.785-1.546内或差值的95%CI在±13%内。
  • 本研究达到主要终点,比值法的95%CI在等效界值内。

临床怎么用

  • SB3可作为参照曲妥珠单抗的生物类似药用于HER2阳性早期乳腺癌的新辅助治疗。
  • 临床使用时需关注其与参照药相似的疗效和安全性特征。

局限性

  • 差值法的95%CI上限超出等效界值,但主要分析基于比值法。
  • 研究仅报告了短期安全性及免疫原性数据(抗药抗体检测至第9周期)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose This phase III study compared SB3, a trastuzumab (TRZ) biosimilar, with reference TRZ in patients with human epidermal growth factor receptor 2-positive early breast cancer in the neoadjuvant setting ( ClinicalTrials.gov identifier: NCT02149524). Patients and Methods Patients were randomly assigned to receive neoadjuvant SB3 or TRZ for eight cycles concurrently with chemotherapy (four cycles of docetaxel followed by four cycles of fluorouracil, epirubicin, and cyclophosphamide) followed by surgery, and then 10 cycles of adjuvant SB3 or TRZ. The primary objective was comparison of breast pathologic complete response (bpCR) rate in the per-protocol set; equivalence was declared if the 95% CI of the ratio was within 0.785 to 1.546 or the 95% CI of the difference was within ± 13%. Secondary end points included comparisons of total pathologic complete response rate, overall response rate, event-free survival, overall survival, safety, pharmacokinetics, and immunogenicity. Results Eight hundred patients were included in the per-protocol set (SB3, n = 402; TRZ, n = 398). The bpCR rates were 51.7% and 42.0% with SB3 and TRZ, respectively. The adjusted ratio of bpCR was 1.259 (95% CI, 1.085 to 1.460), which was within the predefined equivalence margins. The adjusted difference was 10.70% (95% CI, 4.13% to 17.26%), with the lower limit contained within and the upper limit outside the equivalence margin. The total pathologic complete response rates were 45.8% and 35.8% and the overall response rates were 96.3% and 91.2% with SB3 and TRZ, respectively. Overall, 96.6% and 95.2% of patients experienced one or more adverse event, 10.5% and 10.7% had a serious adverse event, and 0.7% and 0.0% had antidrug antibodies (up to cycle 9) with SB3 and TRZ, respectively. Conclusion Equivalence for efficacy was demonstrated between SB3 and TRZ on the basis of the ratio of bpCR rates. Safety and immunogenicity were comparable.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Pivot X, Bondarenko I, Nowecki Z, et al. Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. J Clin Oncol. 2018. PMID: 29373094. doi:10.1200/JCO.2017.74.0126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。